U.S. flag An official website of the United States government
  1. Home
  2. Advisory Committees
  3. Advisory Committee Calendar
  4. June 8, 2022: Meeting of the Pharmacy Compounding Advisory Committee Meeting Announcement - 06/08/2022
  1. Advisory Committee Calendar

Advisory Committee Meeting | Virtual

Event Title
June 8, 2022: Meeting of the Pharmacy Compounding Advisory Committee Meeting Announcement
June 8, 2022


Date:
June 8, 2022

What is an advisory committee?

Advisory committees provide independent expert advice to the FDA on broad scientific topics or on certain products to help the agency make sound decisions based on the available science. Advisory committees make non-binding recommendations to the FDA, which generally follows the recommendations but is not legally bound to do so. Please see, "Advisory Committees Give FDA Critical Advice and the Public a Voice," for more information.

YouTube broadcast of the meeting:

Pharmacy Compounding Advisory Committee (PCAC) Live Video

https://youtu.be/QX-fH9iEsz4

Center Date Time Location
CDER June 8, 2022 9:30 a.m. to 5:15 p.m. Please note that due to the impact of this COVID-19 pandemic, all meeting participants will be joining this advisory committee meeting via an online teleconferencing platform.

Agenda

The meeting presentations will be heard, viewed, captioned, and recorded through an online teleconferencing platform. The committee will discuss the following four bulk drug substances nominated for inclusion on the 503A Bulks List: Ammonium tetrathiomolybdate, enclomiphene citrate, ferric subsulfate, and glutathione. The chart below identifies the use(s) FDA reviewed for each of the four bulk drug substances being discussed at this advisory committee meeting. The nominators of these substances or another interested party will be invited to make a short presentation supporting the nomination.

Bulk Drug Substance Uses Evaluated
Ammonium Tetrathiomolybdate Wilson disease, use as copper (Cu) chelation therapy for the treatment of breast cancer, kidney cancer, prostate cancer, colorectal cancer, esophageal cancer, and malignant pleural mesothelioma.
Enclomiphene Citrate To increase serum testosterone, luteinizing hormone (LH), and follicle-stimulating hormone (FSH) to normal levels in the treatment of secondary hypogonadism.
Ferric Subsulfate For use as an astringent and hemostatic agent during minor
surgical procedures.
Glutathione Skin lightening, cystic fibrosis, asthma, chronic obstructive pulmonary disease, chronic lung disease, oxidative stress, reduction of the side effects of chemotherapy, inhibition of chemical induced carcinogenesis, prevention of radiation injury, treatment of heavy metal poisoning (cadmium and mercury), acetaminophen toxicity, autism spectrum disorder, Alzheimer’s disease, Parkinson’s disease, major depressive disorder, schizophrenia, helicobacter pylori infection, human immunodeficiency virus infection, tuberculosis, otitis media, peripheral obstructive arterial disease, anemia, diabetes, and septic shock.

The committee will also discuss revisions FDA is considering to the Withdrawn or Removed List. FDA now is considering whether to amend the rule to add one more entry to the list: Lorcaserin Hydrochloride: All drug products containing lorcaserin hydrochloride. As previously explained in the Federal Register of July 2, 2014 (79 FR 37687 at 37689 through 37690), the list may specify that a drug may not be compounded in any form, or, alternatively, may expressly exclude a particular formulation, indication, dosage form, or route of administration from an entry on the list. Moreover, a drug may be listed only with regard to certain formulations, indications, routes of administration, or dosage forms because it has been found to be unsafe or not effective in those particular formulations, indications, routes of administration, or dosage forms. FDA plans to seek the committee’s advice concerning the inclusion of this drug on the list.

Meeting Materials

FDA intends to make background material available to the public no later than two (2) business days before the meeting. If FDA is unable to post the background material on its website prior to the meeting, the background material will be made publicly available on FDA’s website at the time of the advisory committee meeting. Background material and the link to the live webcast will be available at 2022 Meeting Materials, Pharmacy Compounding Advisory Committee. Scroll down to the appropriate advisory committee meeting link. The meeting will include slide presentations with audio components to allow the presentation of materials in a manner that most closely resembles an in-person advisory committee meeting.

Public Participation Information

Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee.

FDA is establishing a docket for public comment on this meeting. The docket number is FDA-2021-N-0357. The docket will close on June 7, 2022. Submit either electronic or written comments on this public meeting by June 7, 2022. Please note that late, untimely filed comments will not be considered. Electronic comments must be submitted on or before June 7, 2022. The https://www.regulations.gov electronic filing system will accept comments until 11:59 p.m. Eastern Time at the end of June 7, 2022. Comments received by mail/hand delivery/courier (for written/paper submissions) will be considered timely if they are postmarked or the delivery service acceptance receipt is on or before that date.

Comments received on or before May 24, 2022, will be provided to the committee. Comments received after that date but by June 7, 2022 will be taken into consideration by FDA. In the event that the meeting is cancelled, FDA will continue to evaluate any relevant applications or information, and consider any comments submitted to the docket, as appropriate. You may submit comments as follows:

Electronic Submissions

Submit electronic comments in the following way:

  • Federal eRulemaking Portal: https://www.regulations.gov. Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to https://www.regulations.gov will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else’s Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on https://www.regulations.gov.
  • If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see “Written/Paper Submissions” and “Instructions”).

Written/Paper Submissions

Submit written/paper submissions as follows:

  • Mail/Hand delivery/Courier (for written/paper submissions): Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
  • For written/paper comments submitted to the Division of Dockets Management, FDA will post your comment, as well as any attachments, except for information submitted, marked and identified, as confidential, if submitted as detailed in “Instructions.”

Instructions: All submissions received must include the Docket No. FDA-2021-N-0357 for “Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments.” Received comments, those filed in a timely manner (see ADDRESSES), will be placed in the docket and, except for those submitted as “Confidential Submissions,” publicly viewable at https://www.regulations.gov or at the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through Friday, 240-402-7500.

  • Confidential Submissions--To submit a comment with confidential information that you do not wish to be made publicly available, submit your comments only as a written/paper submission. You should submit two copies total. One copy will include the information you claim to be confidential with a heading or cover note that states “THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.” FDA will review this copy, including the claimed confidential information, in its consideration of comments. The second copy, which will have the claimed confidential information redacted/blacked out, will be available for public viewing and posted on https://www.regulations.gov. Submit both copies to the Dockets Management Staff. If you do not wish your name and contact information be made publicly available, you can provide this information on the cover sheet and not in the body of your comments and you must identify the information as “confidential.” Any information marked as “confidential” will not be disclosed except in accordance with 21 CFR 10.20 and other applicable disclosure law. For more information about FDA’s posting of comments to public dockets, see 80 FR 56469, September 18, 2015, or access the information at: https://www.gpo.gov/fdsys/pkg/FR-2015-09-18/pdf/2015-23389.pdf.

Docket: For access to the docket to read background documents or the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in the heading of this document, into the “Search” box and follow the prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, 240-402-7500.

Oral presentations from the public will be scheduled between approximately 10:35 a.m. to 10:50 a.m., 12:15 p.m. to 12:30 p.m., 2:25 p.m. to 2:40 p.m., 3:45 p.m. to 4 p.m., and 4:50 p.m. to 5:05 p.m. Eastern Time. Those individuals interested in making formal oral presentations should notify the contact person and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation on or before May 16, 2022.

Time allotted for each presentation may be limited. If the number of registrants requesting to speak is greater than can be reasonably accommodated during the scheduled open public hearing session, FDA may conduct a lottery to determine the speakers for the scheduled open public hearing session. The contact person will notify interested persons regarding their request to speak by May 17, 2022.

Webcast Information

CDER plans to provide a free of charge, live webcast of the June 8, 2022 Pharmacy Compounding Advisory Committee meeting. If there are instances where the webcast transmission is not successful, staff will work to re-establish the transmission as soon as possible. Further information regarding the webcast, including the web address for the webcast, will be made available at least 2 days in advance of the meeting at the following website: 2022 Meeting Materials, Pharmacy Compounding Advisory Committee

CDER plans to post archived webcasts after the meeting, however, in cases where transmission was not successful, archived webcasts will not be available.

Contact Information

  • Takyiah Stevenson, PharmD
    Center for Drug Evaluation and Research
    Food and Drug Administration
    10903 New Hampshire Avenue
    WO31-2417
    Silver Spring, MD 20993-0002

    Phone: 240-402-2507
    Fax: 301-847-8533
    Email: PCAC@fda.hhs.gov
  • FDA Advisory Committee Information Line
    1-800-741-8138
    (301-443-0572 in the Washington DC area)
    Please call the Information Line for up-to-date information on this meeting.

 


A notice in the Federal Register about last minute modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice. Therefore, you should always check the agency’s website or call the committee’s Designated Federal Officer (see Contact Information) to learn about possible modifications before coming to the meeting.

Persons attending FDA’s advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets. FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with disabilities. If you require accommodations due to a disability, please contact the committee’s Designated Federal Officer (see Contact Information) at least 7 days in advance of the meeting.

Answers to commonly asked questions including information regarding special accommodations due to a disability may be accessed at: Common Questions and Answers about FDA Advisory Committee Meetings.

FDA is committed to the orderly conduct of its advisory committee meetings. Please visit our Web site at Public Conduct During FDA Advisory Committee Meetings for procedures on public conduct during advisory committee meetings.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app.2).


Event Materials

Title File Type/Size Source Organization
FDA Briefing Information for the June 8, 2022 Meeting of the Pharmacy Compounding Advisory Committee pdf (41.96 MB)
Srinivasan Dasarathy, M.D. 18 U.S.C. 208(b)(3) Waiver for the June 8, 2022 Meeting of the Pharmacy Compounding Advisory Committee pdf (516.54 KB)
Srinivasan Dasarathy, M.D. Disclosure Document for the June 8, 2022 Meeting of the Pharmacy Compounding Advisory Committee pdf (178.67 KB)
Padma Gulur, M.D. 18 U.S.C. 208(b)(3) Waiver for the June 8, 2022 Meeting of the Pharmacy Compounding Advisory Committee pdf (215.55 KB)
Padma Gulur, M.D. Disclosure Document for the June 8, 2022 Meeting of the Pharmacy Compounding Advisory Committee pdf (187.05 KB)
Kathleen Gura, Pharm.D. 18 U.S.C. 208(b)(3) Waiver for the June 8, 2022 Meeting of the Pharmacy Compounding Advisory Committee pdf (397.24 KB)
Kathleen Gura, Pharm.D. Disclosure Document for the June 8, 2022 Meeting of the Pharmacy Compounding Advisory Committee pdf (184.29 KB)
Committee Roster for the June 8, 2022 Meeting of the Pharmacy Compounding Advisory Committee pdf (157.56 KB)
Webcast Information for the June 8, 2022 Meeting of the Pharmacy Compounding Advisory Committee pdf (74.75 KB)
Errata to the FDA Briefing Information for the June 8, 2022 Meeting of the Pharmacy Compounding Advisory Committee pdf (85.92 KB)
Final Agenda for the June 8, 2022 Meeting of the Pharmacy Compounding Advisory Committee pdf (170.29 KB)
Final Meeting Roster for the June 8, 2022 Meeting of the Pharmacy Compounding Advisory Committee pdf (178.08 KB)
Final Questions for the June 8, 2022 Meeting of the Pharmacy Compounding Advisory Committee pdf (159.61 KB)
FDA Presentations for the June 8, 2022 Meeting of the Pharmacy Compounding Advisory Committee pdf (2.43 MB)
Nominator Presentations for the June 8, 2022 Meeting of the Pharmacy Compounding Advisory Committee pdf (8.00 MB)
Minutes for the June 8, 2022 Meeting of the Pharmacy Compounding Advisory Committee pdf (251.65 KB)
Transcript for the June 8, 2022 Meeting of the Pharmacy Compounding Advisory Committee (AM Session) pdf (625.50 KB)
Transcript for the June 8, 2022 Meeting of the Pharmacy Compounding Advisory Committee (PM Session) pdf (549.02 KB)

 
Back to Top